Identification

Name
Sodium phosphate
Accession Number
DB09449  (DB09127, DB11083, DB09524, DB09542, DB09468, DB11084, DB09482, DB09469, DB09525)
Type
Small Molecule
Groups
Approved
Description

Sodium phosphate is a saline laxative that is thought to work by increasing fluid in the small intestine. It usually results in a bowel movement after 30 minutes to 6 hours.

Structure
Thumb
Synonyms
  • Sodium orthophosphate
  • Sodium phosphate monobasic
  • Sodium phosphate monobasic (anhydrate)
  • Sodium phosphate, unspecified
  • Sodium phosphates
External IDs
E-339(I) / INS NO.339(I) / INS-339(I)
Product Ingredients
IngredientUNIICASInChI Key
Sodium phosphate, dibasicBWZ7K44R5110140-65-5LVXHNCUCBXIIPE-UHFFFAOYSA-L
Sodium phosphate, dibasic dihydrate94255I6E2T10028-24-7KDQPSPMLNJTZAL-UHFFFAOYSA-L
Sodium phosphate, dibasic dodecahydrateE1W4N241FO10039-32-4DGLRDKLJZLEJCY-UHFFFAOYSA-L
Sodium phosphate, dibasic, anhydrous22ADO53M6F7558-79-4BNIILDVGGAEEIG-UHFFFAOYSA-L
Sodium phosphate, dibasic, heptahydrate70WT22SF4B7782-85-6PYLIXCKOHOHGKQ-UHFFFAOYSA-L
Sodium phosphate, monobasic, anhydrousNot Available7558-80-7AJPJDKMHJJGVTQ-UHFFFAOYSA-M
Sodium phosphate, monobasic, dihydrate5QWK66595613472-35-0VBJGJHBYWREJQD-UHFFFAOYSA-M
Sodium phosphate, monobasic, monohydrate593YOG76RN10049-21-5BBMHARZCALWXSL-UHFFFAOYSA-M
Sodium phosphate, monobasic, unspecified form3980JIH2SWNot AvailableNot applicable
Product Images
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Additive Solution Formula 3 As-3Sodium phosphate, monobasic, monohydrate (0.276 g) + Adenine (0.030 g) + Citric acid monohydrate (0.042 g) + Glucose (1.10 g) + Sodium Chloride (0.410 g) + Trisodium citrate dihydrate (0.588 g)SolutionUnknownTerumo Bct, Inc.2013-05-31Not applicableCanada
AlphaligoSodium phosphate (125 mg) + Cyanocobalamin (10 mcg) + Magnesium (119 mg) + Manganese (4.5 mg) + Potassium (112.5 mg)TabletOralClinique Lafontaine Inc, Division Les Importations Ortho1998-03-062008-08-07Canada
AminosynSodium phosphate, dibasic (425 mg/100mL) + Glycine (1100 mg/100mL) + Histidine (260 mg/100mL) + L-Alanine (1100 mg/100mL) + L-Arginine (850 mg/100mL) + L-Isoleucine (620 mg/100mL) + L-Leucine (810 mg/100mL) + L-Lysine acetate (624 mg/100mL) + L-Methionine (340 mg/100mL) + L-Phenylalanine (380 mg/100mL) + L-Proline (750 mg/100mL) + L-Threonine (460 mg/100mL) + L-Tryptophan (150 mg/100mL) + L-Tyrosine (44 mg/100mL) + L-Valine (680 mg/100mL) + Magnesium chloride (102 mg/100mL) + Potassium Chloride (487 mg/100mL) + Serine (370 mg/100mL) + Sodium Chloride (28 mg/100mL)Injection, solutionIntravenousHospira, Inc.2011-03-23Not applicableUs
AminosynSodium phosphate, dibasic (425 mg/100mL) + Glycine (900 mg/100mL) + Histidine (210 mg/100mL) + L-Alanine (900 mg/100mL) + L-Arginine (690 mg/100mL) + L-Isoleucine (510 mg/100mL) + L-Leucine (660 mg/100mL) + L-Lysine acetate (510 mg/100mL) + L-Methionine (280 mg/100mL) + L-Phenylalanine (310 mg/100mL) + L-Proline (610 mg/100mL) + L-Threonine (370 mg/100mL) + L-Tryptophan (120 mg/100mL) + L-Tyrosine (44 mg/100mL) + L-Valine (560 mg/100mL) + Magnesium chloride (102 mg/100mL) + Potassium Chloride (487 mg/100mL) + Serine (300 mg/100mL) + Sodium Chloride (28 mg/100mL)Injection, solutionIntravenousHospira, Inc.2011-03-23Not applicableUs
Aminosyn II 7% M In 10% Dextrose(dual Chamber)Sodium phosphate, dibasic, anhydrous (49 mg) + Glucose (5 g) + Glutamic Acid (258 mg) + Glycine (175 mg) + Histidine (105 mg) + L-Alanine (348 mg) + L-Arginine (356 mg) + L-Aspartic Acid (245 mg) + L-Isoleucine (231 mg) + L-Leucine (350 mg) + L-Lysine (368 mg) + L-Methionine (60 mg) + L-Phenylalanine (104 mg) + L-Proline (252 mg) + L-Threonine (140 mg) + L-Tryptophan (70 mg) + L-Valine (175 mg) + Magnesium chloride (30 mg) + N-acetyltyrosine (94 mg) + Potassium Chloride (97 mg) + Serine (186 mg) + Sodium Chloride (120 mg)SolutionIntravenousHospira, Inc.1987-12-312012-08-03Canada
Aminosyn II 8.5% M In 20% Dextrose (dual Chamber)Sodium phosphate, dibasic, anhydrous (49 mg) + Glucose (10 g) + Glutamic Acid (314 mg) + Glycine (212 mg) + Histidine (128 mg) + L-Alanine (422 mg) + L-Arginine (432 mg) + L-Aspartic Acid (298 mg) + L-Isoleucine (280 mg) + L-Leucine (425 mg) + L-Lysine (446 mg) + L-Methionine (73 mg) + L-Phenylalanine (126 mg) + L-Proline (307 mg) + L-Threonine (170 mg) + L-Tryptophan (85 mg) + L-Valine (212 mg) + Magnesium chloride (30 mg) + N-acetyltyrosine (115 mg) + Potassium Chloride (97 mg) + Serine (225 mg) + Sodium Chloride (120 mg)SolutionIntravenousHospira, Inc.1987-12-312012-08-03Canada
Aminosyn II with ElectrolytesSodium phosphate, dibasic (425 mg/100mL) + Glutamic Acid (627 mg/100mL) + Glycine (425 mg/100mL) + Histidine (255 mg/100mL) + L-Alanine (844 mg/100mL) + L-Arginine (865 mg/100mL) + L-Aspartic Acid (595 mg/100mL) + L-Isoleucine (561 mg/100mL) + L-Leucine (850 mg/100mL) + L-Lysine acetate (893 mg/100mL) + L-Methionine (146 mg/100mL) + L-Phenylalanine (253 mg/100mL) + L-Proline (614 mg/100mL) + L-Threonine (340 mg/100mL) + L-Tryptophan (170 mg/100mL) + L-Valine (425 mg/100mL) + Magnesium chloride (102 mg/100mL) + N-acetyltyrosine (230 mg/100mL) + Potassium Chloride (492 mg/100mL) + Serine (450 mg/100mL) + Sodium Chloride (60 mg/100mL)Injection, solutionIntravenousHospira, Inc.1986-04-03Not applicableUs
Amo Endosol ExtraSodium phosphate, dibasic, anhydrous (0.42 mg) + Calcium Chloride (0.154 mg) + Glucose (0.92 mg) + Glutathione disulfide (0.184 mg) + Magnesium chloride (0.2 mg) + Potassium Chloride (0.38 mg) + Sodium Chloride (7.14 mg) + Sodium bicarbonate (2.1 mg)Powder, for solutionIntraocularAmo Canada Company1993-12-312008-07-30Canada
Anticoagulant Cit Phos Dex Adenine Sol USPSodium phosphate (140 mg) + Adenine (17.3 mg) + Citric Acid (189 mg) + Glucose (2 g) + Sodium Citrate (1.66 g)SolutionIntravenousBaxter Laboratories1996-10-17Not applicableCanada
Anticoagulant Citrate Phosphate Dextrose (CPD) Blood-Pack Units in PL 146 PlasticSodium phosphate, monobasic, monohydrate (78 mg/35mL) + Citric Acid (105 mg/35mL) + Dextrose monohydrate (893 mg/35mL) + Trisodium citrate dihydrate (921 mg/35mL)SolutionIntravenousFenwal, Inc.2007-03-01Not applicableUs
Categories
UNII
KH7I04HPUU
CAS number
7632-05-5
Weight
Average: 119.977
Monoisotopic: 119.958839739
Chemical Formula
H2NaO4P
InChI Key
AJPJDKMHJJGVTQ-UHFFFAOYSA-M
InChI
InChI=1S/Na.H3O4P/c;1-5(2,3)4/h;(H3,1,2,3,4)/q+1;/p-1
IUPAC Name
sodium dihydrogen phosphate
SMILES
[Na+].OP(O)([O-])=O

Pharmacology

Indication

Used to treat constipation or to clean the bowel before a colonoscopy [FDA Label].

Structured Indications
Pharmacodynamics

Sodium phosphate inceases fecal water content to increase mobility through the large intestine [1].

Mechanism of action

Sodium phosphate is thought to work by increasing the amount of solute present in the intestinal lumen thereby creating an osmotic gradient which draws water into the lumen [1].

Absorption

Tmax for phosphate absorption with orally administered liquid sodium phosphate is 1-3h [3].

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Intamuscular LD50 of 250mg/kg and oral LD50 of 8290 mg/kg reported in rats [7]. Phosphate toxicity is likely due to the disturbance of other electrolytes when phosphate levels are high, producing symptoms including tetany, dehydration, hypotension, tachycardia, hyperpyrexia, cardiac arrest and coma [4]. Risk of raising phosphate levels through use of sodium phosphate appears to be higher in smaller patients [3].

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AceclofenacSodium phosphate may increase the nephrotoxic activities of Aceclofenac.Approved, Investigational
AcemetacinSodium phosphate may increase the nephrotoxic activities of Acemetacin.Approved, Experimental, Investigational
AcetazolamideAcetazolamide may increase the nephrotoxic activities of Sodium phosphate.Approved, Vet Approved
Acetylsalicylic acidSodium phosphate may increase the nephrotoxic activities of Acetylsalicylic acid.Approved, Vet Approved
AdapaleneSodium phosphate may increase the nephrotoxic activities of Adapalene.Approved
AlclofenacSodium phosphate may increase the nephrotoxic activities of Alclofenac.Approved, Withdrawn
AlmasilateAlmasilate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AlminoprofenSodium phosphate may increase the nephrotoxic activities of Alminoprofen.Experimental
AloglutamolAloglutamol can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AluminiumAluminium can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmilorideAmiloride may increase the nephrotoxic activities of Sodium phosphate.Approved
AmineptineThe risk or severity of adverse effects can be increased when Amineptine is combined with Sodium phosphate.Illicit, Withdrawn
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Sodium phosphate.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Sodium phosphate.Approved
AndrographolideSodium phosphate may increase the nephrotoxic activities of Andrographolide.Investigational
AnisodamineSodium phosphate may increase the nephrotoxic activities of Anisodamine.Investigational
AntipyrineSodium phosphate may increase the nephrotoxic activities of Antipyrine.Approved
ApocyninSodium phosphate may increase the nephrotoxic activities of Apocynin.Investigational
ApremilastSodium phosphate may increase the nephrotoxic activities of Apremilast.Approved, Investigational
AzapropazoneSodium phosphate may increase the nephrotoxic activities of Azapropazone.Withdrawn
AzelastineSodium phosphate may increase the nephrotoxic activities of Azelastine.Approved
Azilsartan medoxomilAzilsartan medoxomil may increase the nephrotoxic activities of Sodium phosphate.Approved
AzosemideAzosemide may increase the nephrotoxic activities of Sodium phosphate.Investigational
BalsalazideSodium phosphate may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BenazeprilBenazepril may increase the nephrotoxic activities of Sodium phosphate.Approved, Investigational
BendazacSodium phosphate may increase the nephrotoxic activities of Bendazac.Experimental
BendroflumethiazideBendroflumethiazide may increase the nephrotoxic activities of Sodium phosphate.Approved
BenorilateSodium phosphate may increase the nephrotoxic activities of Benorilate.Experimental
BenoxaprofenSodium phosphate may increase the nephrotoxic activities of Benoxaprofen.Withdrawn
BenzydamineSodium phosphate may increase the nephrotoxic activities of Benzydamine.Approved
BevoniumSodium phosphate may increase the nephrotoxic activities of Bevonium.Experimental
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
BromfenacSodium phosphate may increase the nephrotoxic activities of Bromfenac.Approved
BucillamineSodium phosphate may increase the nephrotoxic activities of Bucillamine.Investigational
BufexamacSodium phosphate may increase the nephrotoxic activities of Bufexamac.Experimental
BumadizoneSodium phosphate may increase the nephrotoxic activities of Bumadizone.Experimental
BumetanideBumetanide may increase the nephrotoxic activities of Sodium phosphate.Approved
Calcium AcetateCalcium Acetate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium ChlorideCalcium Chloride can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium CitrateCalcium Citrate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium glubionateCalcium glubionate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium GluceptateCalcium Gluceptate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium gluconateCalcium gluconate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Calcium lactateCalcium lactate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateCalcium lactate gluconate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium laevulateCalcium laevulate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium pangamateCalcium pangamate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium PhosphateCalcium Phosphate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium silicateCalcium silicate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CandesartanCandesartan may increase the nephrotoxic activities of Sodium phosphate.Experimental
Candesartan cilexetilCandesartan cilexetil may increase the nephrotoxic activities of Sodium phosphate.Approved
CandoxatrilCandoxatril may increase the nephrotoxic activities of Sodium phosphate.Experimental
Canrenoic acidCanrenoic acid may increase the nephrotoxic activities of Sodium phosphate.Approved, Withdrawn
CanrenoneCanrenone may increase the nephrotoxic activities of Sodium phosphate.Investigational
CaptoprilCaptopril may increase the nephrotoxic activities of Sodium phosphate.Approved
CarprofenSodium phosphate may increase the nephrotoxic activities of Carprofen.Approved, Vet Approved, Withdrawn
CaseinCasein can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CastanospermineSodium phosphate may increase the nephrotoxic activities of Castanospermine.Experimental
CelecoxibSodium phosphate may increase the nephrotoxic activities of Celecoxib.Approved, Investigational
ChloroquineSodium phosphate may increase the nephrotoxic activities of Chloroquine.Approved, Vet Approved
ChlorothiazideChlorothiazide may increase the nephrotoxic activities of Sodium phosphate.Approved, Vet Approved
ChlorthalidoneChlorthalidone may increase the nephrotoxic activities of Sodium phosphate.Approved
Choline magnesium trisalicylateSodium phosphate may increase the nephrotoxic activities of Choline magnesium trisalicylate.Approved
CicletanineCicletanine may increase the nephrotoxic activities of Sodium phosphate.Investigational
CilazaprilCilazapril may increase the nephrotoxic activities of Sodium phosphate.Approved
ClofenamideClofenamide may increase the nephrotoxic activities of Sodium phosphate.Experimental
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Sodium phosphate.Approved, Vet Approved
ClonixinSodium phosphate may increase the nephrotoxic activities of Clonixin.Approved
ClopamideClopamide may increase the nephrotoxic activities of Sodium phosphate.Experimental
ClorexoloneClorexolone may increase the nephrotoxic activities of Sodium phosphate.Experimental
ConivaptanConivaptan may increase the nephrotoxic activities of Sodium phosphate.Approved, Investigational
CurcuminSodium phosphate may increase the nephrotoxic activities of Curcumin.Investigational
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Sodium phosphate.Approved
CyclopenthiazideCyclopenthiazide may increase the nephrotoxic activities of Sodium phosphate.Experimental
CyclothiazideCyclothiazide may increase the nephrotoxic activities of Sodium phosphate.Approved
D-LimoneneSodium phosphate may increase the nephrotoxic activities of D-Limonene.Investigational
DelaprilDelapril may increase the nephrotoxic activities of Sodium phosphate.Experimental
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Sodium phosphate.Approved
DibenzepinThe risk or severity of adverse effects can be increased when Dibenzepin is combined with Sodium phosphate.Experimental
DiclofenacSodium phosphate may increase the nephrotoxic activities of Diclofenac.Approved, Vet Approved
DifenpiramideSodium phosphate may increase the nephrotoxic activities of Difenpiramide.Experimental
DiflunisalSodium phosphate may increase the nephrotoxic activities of Diflunisal.Approved
DosulepinThe risk or severity of adverse effects can be increased when Dosulepin is combined with Sodium phosphate.Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Sodium phosphate.Approved
DrospirenoneDrospirenone may increase the nephrotoxic activities of Sodium phosphate.Approved
DroxicamSodium phosphate may increase the nephrotoxic activities of Droxicam.Approved
DuvelisibSodium phosphate may increase the nephrotoxic activities of Duvelisib.Investigational
E-6201Sodium phosphate may increase the nephrotoxic activities of E-6201.Investigational
EfonidipineEfonidipine may increase the nephrotoxic activities of Sodium phosphate.Approved, Investigational
EnalaprilEnalapril may increase the nephrotoxic activities of Sodium phosphate.Approved, Vet Approved
EnalaprilatEnalaprilat may increase the nephrotoxic activities of Sodium phosphate.Approved
EpirizoleSodium phosphate may increase the nephrotoxic activities of Epirizole.Approved
EplerenoneEplerenone may increase the nephrotoxic activities of Sodium phosphate.Approved
EprosartanEprosartan may increase the nephrotoxic activities of Sodium phosphate.Approved
EsmirtazapineThe risk or severity of adverse effects can be increased when Esmirtazapine is combined with Sodium phosphate.Investigational
Etacrynic acidEtacrynic acid may increase the nephrotoxic activities of Sodium phosphate.Approved
EtanerceptSodium phosphate may increase the nephrotoxic activities of Etanercept.Approved, Investigational
EthenzamideSodium phosphate may increase the nephrotoxic activities of Ethenzamide.Experimental
EthoxzolamideEthoxzolamide may increase the nephrotoxic activities of Sodium phosphate.Withdrawn
EtodolacSodium phosphate may increase the nephrotoxic activities of Etodolac.Approved, Investigational, Vet Approved
EtofenamateSodium phosphate may increase the nephrotoxic activities of Etofenamate.Approved, Investigational
EtoricoxibSodium phosphate may increase the nephrotoxic activities of Etoricoxib.Approved, Investigational
Evening primrose oilSodium phosphate may increase the nephrotoxic activities of Evening primrose oil.Approved, Investigational
exisulindSodium phosphate may increase the nephrotoxic activities of exisulind.Investigational
FelbinacSodium phosphate may increase the nephrotoxic activities of Felbinac.Experimental
FenbufenSodium phosphate may increase the nephrotoxic activities of Fenbufen.Approved
FenoprofenSodium phosphate may increase the nephrotoxic activities of Fenoprofen.Approved
FenquizoneFenquizone may increase the nephrotoxic activities of Sodium phosphate.Experimental
FentiazacSodium phosphate may increase the nephrotoxic activities of Fentiazac.Experimental
FeprazoneSodium phosphate may increase the nephrotoxic activities of Feprazone.Experimental
Ferric CarboxymaltoseFerric Carboxymaltose can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric CitrateFerric Citrate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Ferric pyrophosphateFerric pyrophosphate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferulic acidSodium phosphate may increase the nephrotoxic activities of Ferulic acid.Experimental
FimasartanFimasartan may increase the nephrotoxic activities of Sodium phosphate.Approved, Investigational
FloctafenineSodium phosphate may increase the nephrotoxic activities of Floctafenine.Approved, Withdrawn
FlunixinSodium phosphate may increase the nephrotoxic activities of Flunixin.Vet Approved
FlunoxaprofenSodium phosphate may increase the nephrotoxic activities of Flunoxaprofen.Experimental
FlurbiprofenSodium phosphate may increase the nephrotoxic activities of Flurbiprofen.Approved, Investigational
ForasartanForasartan may increase the nephrotoxic activities of Sodium phosphate.Experimental
FosinoprilFosinopril may increase the nephrotoxic activities of Sodium phosphate.Approved
FurosemideFurosemide may increase the nephrotoxic activities of Sodium phosphate.Approved, Vet Approved
GuacetisalSodium phosphate may increase the nephrotoxic activities of Guacetisal.Experimental
HigenamineSodium phosphate may increase the nephrotoxic activities of Higenamine.Investigational
HydrochlorothiazideHydrochlorothiazide may increase the nephrotoxic activities of Sodium phosphate.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the nephrotoxic activities of Sodium phosphate.Approved, Investigational
HydrotalciteHydrotalcite can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
IbopamineIbopamine may increase the nephrotoxic activities of Sodium phosphate.Experimental
IbuprofenSodium phosphate may increase the nephrotoxic activities of Ibuprofen.Approved
IbuproxamSodium phosphate may increase the nephrotoxic activities of Ibuproxam.Withdrawn
IcatibantSodium phosphate may increase the nephrotoxic activities of Icatibant.Approved
ImidaprilImidapril may increase the nephrotoxic activities of Sodium phosphate.Investigational
Imidazole salicylateSodium phosphate may increase the nephrotoxic activities of Imidazole salicylate.Experimental
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Sodium phosphate.Approved
IndapamideIndapamide may increase the nephrotoxic activities of Sodium phosphate.Approved
IndobufenSodium phosphate may increase the nephrotoxic activities of Indobufen.Investigational
IndomethacinSodium phosphate may increase the nephrotoxic activities of Indomethacin.Approved, Investigational
IndoprofenSodium phosphate may increase the nephrotoxic activities of Indoprofen.Withdrawn
IprindoleThe risk or severity of adverse effects can be increased when Iprindole is combined with Sodium phosphate.Experimental
IrbesartanIrbesartan may increase the nephrotoxic activities of Sodium phosphate.Approved, Investigational
IronIron can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranIron Dextran can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Iron saccharateIron saccharate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IsosorbideIsosorbide may increase the nephrotoxic activities of Sodium phosphate.Approved, Investigational
IsoxicamSodium phosphate may increase the nephrotoxic activities of Isoxicam.Withdrawn
KebuzoneSodium phosphate may increase the nephrotoxic activities of Kebuzone.Experimental
KetoprofenSodium phosphate may increase the nephrotoxic activities of Ketoprofen.Approved, Vet Approved
KetorolacSodium phosphate may increase the nephrotoxic activities of Ketorolac.Approved
LeflunomideSodium phosphate may increase the nephrotoxic activities of Leflunomide.Approved, Investigational
LisinoprilLisinopril may increase the nephrotoxic activities of Sodium phosphate.Approved, Investigational
LisofyllineSodium phosphate may increase the nephrotoxic activities of Lisofylline.Investigational
LofepramineThe risk or severity of adverse effects can be increased when Lofepramine is combined with Sodium phosphate.Experimental
LonazolacSodium phosphate may increase the nephrotoxic activities of Lonazolac.Experimental
LornoxicamSodium phosphate may increase the nephrotoxic activities of Lornoxicam.Approved, Investigational
LosartanLosartan may increase the nephrotoxic activities of Sodium phosphate.Approved
LoxoprofenSodium phosphate may increase the nephrotoxic activities of Loxoprofen.Approved, Investigational
LumiracoxibSodium phosphate may increase the nephrotoxic activities of Lumiracoxib.Approved, Investigational
MagaldrateMagaldrate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium HydroxideThe serum concentration of Sodium phosphate can be decreased when it is combined with Magnesium Hydroxide.Approved
Magnesium oxideThe serum concentration of Sodium phosphate can be decreased when it is combined with Magnesium oxide.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium salicylateSodium phosphate may increase the nephrotoxic activities of Magnesium salicylate.Approved
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Magnesium SulfateThe serum concentration of Sodium phosphate can be decreased when it is combined with Magnesium Sulfate.Approved, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MannitolMannitol may increase the nephrotoxic activities of Sodium phosphate.Approved, Investigational
MasoprocolSodium phosphate may increase the nephrotoxic activities of Masoprocol.Approved, Investigational
MebutizideMebutizide may increase the nephrotoxic activities of Sodium phosphate.Experimental
Meclofenamic acidSodium phosphate may increase the nephrotoxic activities of Meclofenamic acid.Approved, Vet Approved
Mefenamic acidSodium phosphate may increase the nephrotoxic activities of Mefenamic acid.Approved
MefrusideMefruside may increase the nephrotoxic activities of Sodium phosphate.Experimental
MeloxicamSodium phosphate may increase the nephrotoxic activities of Meloxicam.Approved, Vet Approved
MersalylMersalyl may increase the nephrotoxic activities of Sodium phosphate.Approved
MesalazineSodium phosphate may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleSodium phosphate may increase the nephrotoxic activities of Metamizole.Investigational, Withdrawn
MethazolamideMethazolamide may increase the nephrotoxic activities of Sodium phosphate.Approved
MethyclothiazideMethyclothiazide may increase the nephrotoxic activities of Sodium phosphate.Approved
MeticraneMeticrane may increase the nephrotoxic activities of Sodium phosphate.Experimental
MetolazoneMetolazone may increase the nephrotoxic activities of Sodium phosphate.Approved
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Sodium phosphate.Approved
MizoribineSodium phosphate may increase the nephrotoxic activities of Mizoribine.Investigational
MoexiprilMoexipril may increase the nephrotoxic activities of Sodium phosphate.Approved
MofebutazoneSodium phosphate may increase the nephrotoxic activities of Mofebutazone.Experimental
MuzolimineMuzolimine may increase the nephrotoxic activities of Sodium phosphate.Experimental
Mycophenolate mofetilSodium phosphate may increase the nephrotoxic activities of Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidSodium phosphate may increase the nephrotoxic activities of Mycophenolic acid.Approved
NabumetoneSodium phosphate may increase the nephrotoxic activities of Nabumetone.Approved
NafamostatSodium phosphate may increase the nephrotoxic activities of Nafamostat.Approved, Investigational
NaftifineSodium phosphate may increase the nephrotoxic activities of Naftifine.Approved
NaproxenSodium phosphate may increase the nephrotoxic activities of Naproxen.Approved, Vet Approved
NepafenacSodium phosphate may increase the nephrotoxic activities of Nepafenac.Approved
NifenazoneSodium phosphate may increase the nephrotoxic activities of Nifenazone.Experimental
Niflumic AcidSodium phosphate may increase the nephrotoxic activities of Niflumic Acid.Approved
NimesulideSodium phosphate may increase the nephrotoxic activities of Nimesulide.Approved, Investigational, Withdrawn
NitroaspirinSodium phosphate may increase the nephrotoxic activities of Nitroaspirin.Investigational
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Sodium phosphate.Approved
OlmesartanOlmesartan may increase the nephrotoxic activities of Sodium phosphate.Approved, Investigational
OlopatadineSodium phosphate may increase the nephrotoxic activities of Olopatadine.Approved
OlsalazineSodium phosphate may increase the nephrotoxic activities of Olsalazine.Approved
OmapatrilatOmapatrilat may increase the nephrotoxic activities of Sodium phosphate.Investigational
OpipramolThe risk or severity of adverse effects can be increased when Opipramol is combined with Sodium phosphate.Investigational
OrgoteinSodium phosphate may increase the nephrotoxic activities of Orgotein.Vet Approved
OxaprozinSodium phosphate may increase the nephrotoxic activities of Oxaprozin.Approved
OxyphenbutazoneSodium phosphate may increase the nephrotoxic activities of Oxyphenbutazone.Approved, Withdrawn
PamabromPamabrom may increase the nephrotoxic activities of Sodium phosphate.Approved
ParecoxibSodium phosphate may increase the nephrotoxic activities of Parecoxib.Approved
ParthenolideSodium phosphate may increase the nephrotoxic activities of Parthenolide.Investigational
PerindoprilPerindopril may increase the nephrotoxic activities of Sodium phosphate.Approved
PhenylbutazoneSodium phosphate may increase the nephrotoxic activities of Phenylbutazone.Approved, Vet Approved
PimecrolimusSodium phosphate may increase the nephrotoxic activities of Pimecrolimus.Approved, Investigational
PiretanidePiretanide may increase the nephrotoxic activities of Sodium phosphate.Experimental
PirfenidoneSodium phosphate may increase the nephrotoxic activities of Pirfenidone.Approved, Investigational
PiroxicamSodium phosphate may increase the nephrotoxic activities of Piroxicam.Approved, Investigational
PirprofenSodium phosphate may increase the nephrotoxic activities of Pirprofen.Experimental
PolythiazidePolythiazide may increase the nephrotoxic activities of Sodium phosphate.Approved
PotassiumPotassium may increase the nephrotoxic activities of Sodium phosphate.Approved
Potassium CitratePotassium Citrate may increase the nephrotoxic activities of Sodium phosphate.Approved, Vet Approved
PranoprofenSodium phosphate may increase the nephrotoxic activities of Pranoprofen.Experimental, Investigational
ProglumetacinSodium phosphate may increase the nephrotoxic activities of Proglumetacin.Experimental
PropacetamolSodium phosphate may increase the nephrotoxic activities of Propacetamol.Approved, Investigational
PropyphenazoneSodium phosphate may increase the nephrotoxic activities of Propyphenazone.Experimental
ProquazoneSodium phosphate may increase the nephrotoxic activities of Proquazone.Experimental
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Sodium phosphate.Approved
PTC299Sodium phosphate may increase the nephrotoxic activities of PTC299.Investigational
QuinaprilQuinapril may increase the nephrotoxic activities of Sodium phosphate.Approved, Investigational
QuinethazoneQuinethazone may increase the nephrotoxic activities of Sodium phosphate.Approved
RamiprilRamipril may increase the nephrotoxic activities of Sodium phosphate.Approved
RescinnamineRescinnamine may increase the nephrotoxic activities of Sodium phosphate.Approved
ResveratrolSodium phosphate may increase the nephrotoxic activities of Resveratrol.Approved, Experimental, Investigational
RofecoxibSodium phosphate may increase the nephrotoxic activities of Rofecoxib.Investigational, Withdrawn
RolofyllineRolofylline may increase the nephrotoxic activities of Sodium phosphate.Investigational
SacubitrilSacubitril may increase the nephrotoxic activities of Sodium phosphate.Approved
SalicylamideSodium phosphate may increase the nephrotoxic activities of Salicylamide.Approved
Salicylic acidSodium phosphate may increase the nephrotoxic activities of Salicylic acid.Approved, Vet Approved
SalsalateSodium phosphate may increase the nephrotoxic activities of Salsalate.Approved
SaprisartanSaprisartan may increase the nephrotoxic activities of Sodium phosphate.Experimental
SaralasinSaralasin may increase the nephrotoxic activities of Sodium phosphate.Investigational
SemapimodSodium phosphate may increase the nephrotoxic activities of Semapimod.Investigational
SeratrodastSodium phosphate may increase the nephrotoxic activities of Seratrodast.Approved
SerrapeptaseSodium phosphate may increase the nephrotoxic activities of Serrapeptase.Investigational
Sodium bicarbonateSodium bicarbonate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SpiradolineSpiradoline may increase the nephrotoxic activities of Sodium phosphate.Investigational
SpiraprilSpirapril may increase the nephrotoxic activities of Sodium phosphate.Approved
SpironolactoneSpironolactone may increase the nephrotoxic activities of Sodium phosphate.Approved
SRT501Sodium phosphate may increase the nephrotoxic activities of SRT501.Investigational
SucralfateSucralfate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SulfasalazineSodium phosphate may increase the nephrotoxic activities of Sulfasalazine.Approved
SulindacSodium phosphate may increase the nephrotoxic activities of Sulindac.Approved
SuprofenSodium phosphate may increase the nephrotoxic activities of Suprofen.Approved, Withdrawn
SuxibuzoneSodium phosphate may increase the nephrotoxic activities of Suxibuzone.Experimental
TarenflurbilSodium phosphate may increase the nephrotoxic activities of Tarenflurbil.Investigational
TasosartanTasosartan may increase the nephrotoxic activities of Sodium phosphate.Approved
TelmisartanTelmisartan may increase the nephrotoxic activities of Sodium phosphate.Approved, Investigational
TemocaprilTemocapril may increase the nephrotoxic activities of Sodium phosphate.Experimental, Investigational
TenidapSodium phosphate may increase the nephrotoxic activities of Tenidap.Experimental
TenoxicamSodium phosphate may increase the nephrotoxic activities of Tenoxicam.Approved
TepoxalinSodium phosphate may increase the nephrotoxic activities of Tepoxalin.Vet Approved
TeriflunomideSodium phosphate may increase the nephrotoxic activities of Teriflunomide.Approved
TheobromineTheobromine may increase the nephrotoxic activities of Sodium phosphate.Approved, Investigational
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Sodium phosphate.Approved, Investigational
Tiaprofenic acidSodium phosphate may increase the nephrotoxic activities of Tiaprofenic acid.Approved
TicrynafenTicrynafen may increase the nephrotoxic activities of Sodium phosphate.Withdrawn
TinoridineSodium phosphate may increase the nephrotoxic activities of Tinoridine.Investigational
Tolfenamic AcidSodium phosphate may increase the nephrotoxic activities of Tolfenamic Acid.Approved
TolmetinSodium phosphate may increase the nephrotoxic activities of Tolmetin.Approved
TolvaptanTolvaptan may increase the nephrotoxic activities of Sodium phosphate.Approved
TorasemideTorasemide may increase the nephrotoxic activities of Sodium phosphate.Approved
TrandolaprilTrandolapril may increase the nephrotoxic activities of Sodium phosphate.Approved
TranilastSodium phosphate may increase the nephrotoxic activities of Tranilast.Approved, Investigational
TriamtereneTriamterene may increase the nephrotoxic activities of Sodium phosphate.Approved
TribenosideSodium phosphate may increase the nephrotoxic activities of Tribenoside.Experimental
TrichlormethiazideTrichlormethiazide may increase the nephrotoxic activities of Sodium phosphate.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Sodium phosphate.Approved
TriptolideSodium phosphate may increase the nephrotoxic activities of Triptolide.Investigational
TromethamineTromethamine can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
UlaritideUlaritide may increase the nephrotoxic activities of Sodium phosphate.Investigational
ValdecoxibSodium phosphate may increase the nephrotoxic activities of Valdecoxib.Investigational, Withdrawn
ValsartanValsartan may increase the nephrotoxic activities of Sodium phosphate.Approved, Investigational
XipamideXipamide may increase the nephrotoxic activities of Sodium phosphate.Experimental
ZaltoprofenSodium phosphate may increase the nephrotoxic activities of Zaltoprofen.Approved, Investigational
ZileutonSodium phosphate may increase the nephrotoxic activities of Zileuton.Approved, Investigational, Withdrawn
ZofenoprilZofenopril may increase the nephrotoxic activities of Sodium phosphate.Experimental
ZomepiracSodium phosphate may increase the nephrotoxic activities of Zomepirac.Withdrawn
Food Interactions
Not Available

References

General References
  1. Rex DK: Dosing considerations in the use of sodium phosphate bowel preparations for colonoscopy. Ann Pharmacother. 2007 Sep;41(9):1466-75. Epub 2007 Jul 24. [PubMed:17652123]
  2. Schanz S, Kruis W, Mickisch O, Kuppers B, Berg P, Frick B, Heiland G, Huppe D, Schenck B, Horstkotte H, Winkler A: Bowel Preparation for Colonoscopy with Sodium Phosphate Solution versus Polyethylene Glycol-Based Lavage: A Multicenter Trial. Diagn Ther Endosc. 2008;2008:713521. doi: 10.1155/2008/713521. [PubMed:18645612]
  3. Ehrenpreis ED: Increased serum phosphate levels and calcium fluxes are seen in smaller individuals after a single dose of sodium phosphate colon cleansing solution: a pharmacokinetic analysis. Aliment Pharmacol Ther. 2009 Jun 1;29(11):1202-11. doi: 10.1111/j.1365-2036.2009.03987.x. Epub 2009 Feb 27. [PubMed:19298584]
  4. Razzaque MS: Phosphate toxicity: new insights into an old problem. Clin Sci (Lond). 2011 Feb;120(3):91-7. doi: 10.1042/CS20100377. [PubMed:20958267]
  5. Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [PubMed:23398154]
  6. FDA Guide: Sodium Phosphate Tablet [Link]
  7. ChemIDPlus: Sodium Phosphate [Link]
External Links
PubChem Compound
23672064
PubChem Substance
347827853
ChemSpider
22626
ChEBI
37585
ChEMBL
CHEMBL1368
Wikipedia
Sodium_phosphates
ATC Codes
A06AD17 — Sodium phosphateB05XA09 — Sodium phosphateA06AG01 — Sodium phosphate
FDA label
Download (359 KB)
MSDS
Download (84.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedPreventionPlasmodium Infections1
2CompletedBasic ScienceColonoscopy1
2CompletedScreeningHealthy Volunteers1
3Active Not RecruitingTreatmentX-Linked Hypophosphatemia1
3CompletedNot AvailableColonoscopy1
3CompletedDiagnosticBowel Preparation, Efficacy, Tolerability, Safety1
3CompletedTreatmentCataracts2
3CompletedTreatmentColon Cleansing1
3CompletedTreatmentColonoscopy2
4CompletedNot AvailableEye Dryness1
4CompletedDiagnosticColonoscopy1
4CompletedTreatmentColonoscopy2
4CompletedTreatmentColorectal Cleansing Prior Operation1
4CompletedTreatmentPsoriasis / Sleep Apnea, Obstructive1
4Not Yet RecruitingNot AvailableSickle Cell Disorders1
4Not Yet RecruitingBasic ScienceHeart Defects,Congenital1
4RecruitingTreatmentTransient Hypoparathyroidism1
4Unknown StatusTreatmentColon Cleansing1
Not AvailableCompletedOtherLaparoscopic Hysterectomy and/or Laparoscopic Sacrocolpopexy1
Not AvailableCompletedScreeningColorectal Cancers1
Not AvailableRecruitingNot AvailableChronic Kidney Disease (CKD)1
Not AvailableRecruitingNot AvailableHealthy Adults1
Not AvailableTerminatedTreatmentColonoscopy1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
SolutionUnknown
TabletOral
Powder, for solutionIntraocular
Injection, solutionIntravenous
Kit
Kit; solutionIntraocular
LiquidIntravenous
SolutionIntravenous
PasteDental
KitIntravenous
LiquidRectal
SolutionExtracorporeal
LiquidIntravesical
LiquidBuccal
SprayBuccal
Kit; solutionIntraocular; Irrigation
LiquidTopical
Tablet, effervescentOral
RinseDental
SolutionOral
EnemaRectal
LiquidOral
SolutionRespiratory (inhalation)
PowderOral
IrrigantIrrigation
LiquidIrrigation
CapsuleOral
Tablet, coatedOral
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7687075No2008-06-222028-06-22Us
US7084130No2001-11-292021-11-29Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)Decomposes at 75MSDS
water solubility121 g/LMSDS
Predicted Properties
PropertyValueSource
logP-1ChemAxon
pKa (Strongest Acidic)1.8ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area80.59 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity13.53 m3·mol-1ChemAxon
Polarizability5.53 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available

Taxonomy

Description
This compound belongs to the class of inorganic compounds known as alkali metal phosphates. These are inorganic compounds in which the largest oxoanion is phosphate, and in which the heaviest atom not in an oxoanion is an alkali metal.
Kingdom
Inorganic compounds
Super Class
Mixed metal/non-metal compounds
Class
Alkali metal oxoanionic compounds
Sub Class
Alkali metal phosphates
Direct Parent
Alkali metal phosphates
Alternative Parents
Inorganic sodium salts / Inorganic oxides
Substituents
Alkali metal phosphate / Inorganic sodium salt / Inorganic oxide / Inorganic salt
Molecular Framework
Not Available
External Descriptors
sodium phosphate (CHEBI:37585)

Transporters

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Not Available
Specific Function
Not Available
Gene Name
SLC20A1
Uniprot ID
Q8WUM9
Uniprot Name
Sodium-dependent phosphate transporter 1
Molecular Weight
73699.01 Da
References
  1. Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [PubMed:23398154]
Kind
Protein
Organism
Homo sapiens
Pharmacological action
No
Actions
Substrate
General Function
Virus receptor activity
Specific Function
Sodium-phosphate symporter which seems to play a fundamental housekeeping role in phosphate transport by absorbing phosphate from interstitial fluid for normal cellular functions such as cellular m...
Gene Name
SLC20A2
Uniprot ID
Q08357
Uniprot Name
Sodium-dependent phosphate transporter 2
Molecular Weight
70391.755 Da
References
  1. Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [PubMed:23398154]
Kind
Protein
Organism
Homo sapiens
Pharmacological action
No
Actions
Substrate
General Function
Sodium:phosphate symporter activity
Specific Function
Involved in actively transporting phosphate into cells via Na(+) cotransport in the renal brush border membrane. Probably mediates 70-80% of the apical influx.
Gene Name
SLC34A1
Uniprot ID
Q06495
Uniprot Name
Sodium-dependent phosphate transport protein 2A
Molecular Weight
68936.53 Da
References
  1. Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [PubMed:23398154]
Kind
Protein
Organism
Homo sapiens
Pharmacological action
No
Actions
Substrate
General Function
Sodium:phosphate symporter activity
Specific Function
May be involved in actively transporting phosphate into cells via Na(+) cotransport. It may be the main phosphate transport protein in the intestinal brush border membrane. May have a role in the s...
Gene Name
SLC34A2
Uniprot ID
O95436
Uniprot Name
Sodium-dependent phosphate transport protein 2B
Molecular Weight
75758.535 Da
References
  1. Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [PubMed:23398154]
Kind
Protein
Organism
Homo sapiens
Pharmacological action
No
Actions
Substrate
General Function
Sodium:phosphate symporter activity
Specific Function
May be involved in actively transporting phosphate into cells via Na(+) cotransport in the renal brush border membrane. Probably mediates 20-30% of the apical influx.
Gene Name
SLC34A3
Uniprot ID
Q8N130
Uniprot Name
Sodium-dependent phosphate transport protein 2C
Molecular Weight
63548.94 Da
References
  1. Kirchheiner J, Meineke I, Muller G, Roots I, Brockmoller J: Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics. 2002 Oct;12(7):571-80. [PubMed:12360109]

Drug created on November 30, 2015 12:10 / Updated on December 12, 2017 10:05